ÂÜÀòÂÒÂ×

Venkata Bobba is a Principal Scientist in Cell Therapy Development at Bristol Myers Squibb, where they lead the development and qualification of analytical methods for CAR-T manufacturing processes. With nearly a decade of experience at the intersection of analytical chemistry and therapeutic development, Venkata has contributed to some of the industry's first standardized methods for CRISPR-Cas12a RNPs. They hold a Ph.D. in Clinical and Bio-Analytical Chemistry from Cleveland State University and previously served as a Graduate Teaching Assistant there. Venkata's expertise encompasses a wide range of analytical techniques, which they utilize to ensure regulatory compliance and drive innovation in life-changing therapies.